Skip to main content

Table 1 Patient characteristics at initial diagnosis of breast cancer

From: Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy

  

Dose (Gy)

 
 

All patients

<66

≥66

 
 

Median

Range

Median

Range

Median

Range

 

Age at initial diagnosis (years)

 

46

25–77

47

26–77

44

25–77

 

Age at LRR (years)

 

48

25–78

50

26–78

46.5

25–77

 

F/U from initial diagnosis (mos)

 

145

6–390

140

20–382

148

6–390

 

F/U from XRT

 

94

1–218

108

1–218

92

4–164

 

Stage

 

n

%

n

%

n

%

p-value

 

T1

55

34.6%

26

40.0%

29

30.9%

NS

 

T2

76

47.8%

31

47.7%

45

47.9%

 
 

T3

14

8.8%

3

4.6%

11

11.7%

 
 

T4

7

4.4%

2

3.1%

5

5.3%

 
 

TX

7

4.4%

3

4.6%

4

4.3%

 
 

N0

81

50.9%

34

52.3%

47

50.0%

NS

 

N1

52

32.7%

23

35.4%

29

30.9%

 
 

N2

14

8.8%

6

9.2%

8

8.5%

 
 

N3

8

5.0%

1

1.5%

7

7.4%

 
 

NX

4

2.5%

1

1.5%

3

3.2%

 

Primary histopathology

        
 

IDC

141

88.7%

56

86.2%

85

90.4%

NS

 

ILC

18

11.3%

9

13.8%

9

9.6%

 

Tumor Grade

        
 

Well Diff

10

6.3%

2

3.1%

8

8.5%

NS

 

Mod Diff

43

27.0%

17

26.2%

26

27.7%

 
 

Poor Diff

86

54.1%

37

56.9%

49

52.1%

 
 

Unk

20

12.6%

9

13.8%

11

11.7%

 

Markers

        
 

ER

       
 

Negative

70

44.0%

34

52.3%

36

38.3%

0.008

 

Positive

69

43.4%

19

29.2%

50

53.2%

 
 

Not done/Unknown

20

12.6%

12

18.5%

8

8.5%

 
 

PR

       
 

Negative

69

43.4%

32

49.2%

37

39.4%

NS

 

Positive

65

40.9%

20

30.8%

45

47.9%

 
 

Not done/Unknown

25

15.7%

13

20.0%

12

12.8%

 
 

Her2

       
 

Negative

30

18.9%

10

15.4%

20

21.3%

NS

 

Positive

15

9.4%

5

7.7%

10

10.6%

 
 

Unknown/not done

114

71.7%

50

76.9%

64

68.1%

 

Initial systemic therapy

        
 

Hormonal therapy only

16

10.1%

7

10.8%

9

9.6%

0.05

 

Chemotherapy only

66

41.5%

21

32.3%

45

47.9%

 
 

Chemotherapy and hormonal therapy

32

20.1%

11

16.9%

21

22.3%

 
 

None

45

28.3%

26

40.0%

19

20.2%

 

Initial surgery

        
 

MRM

141

88.7%

59

90.8%

82

87.2%

NS

 

Other

18

11.3%

6

9.2%

12

12.8%

 

Menopausal status

        
 

Pre

67

42.1%

28

43.1%

39

41.5%

NS

 

Peri

18

11.3%

5

7.7%

13

13.8%

 
 

Post

63

39.6%

27

41.5%

36

38.3%

 
 

Unknown

11

6.9%

5

7.7%

6

6.4%

 

Race

        
 

Asian

11

6.9%

6

9.2%

5

5.3%

NS

 

Black

27

17.0%

7

10.8%

20

21.3%

 
 

Hispanic

19

11.9%

11

16.9%

8

8.5%

 
 

Other

2

1.3%

1

1.5%

1

1.1%

 
 

White

100

62.9%

40

61.5%

60

63.8%

 
  1. Comparison between escalated (≥66) and standard dose (<66) groups at time of initial treatment. ER positivity was significantly less in the standard dose group (p = 0.008). No other significant differences in patient characteristics at diagnosis between groups were seen.